Trypanosome resistance to human innate immunity: Targeting Achilles' heel

Trends in Parasitology

Volumn 28, Issue 12, 2012, Pages 539-545

  Stephens, Natalie A ^a   Kieft, Rudo ^a   MacLeod, Annette ^b   Hajduk, Stephen L ^a  

^a University of Georgia ^*  (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

African trypanosomes; Apolipoprotein L 1; Haptoglobin; Haptoglobin related protein; High density lipoproteins; Innate immunity; Serum resistance associated protein; Trypanosome lytic factor

Indexed keywords

HAPTOGLOBIN; HEMOGLOBIN; TOXIN; TRYPANOSOME LYTIC FACTOR; UNCLASSIFIED DRUG;

ACHILLES TENDON; AFRICAN TRYPANOSOMIASIS; CYTOLYSIS; GENE FUNCTION; HUMAN; INNATE IMMUNITY; LYSOSOME; MEMBRANE DAMAGE; MICROBIAL GENETICS; NONHUMAN; REVIEW; SERUM RESISTANCE ASSOCIATED GENE; TRYPANOSOMA; TRYPANOSOMA BRUCEI; TRYPANOSOMA GAMBIENSE; TRYPANOSOMA RHODESIENSE;

ANIMALS; BIOLOGICAL EVOLUTION; HUMANS; IMMUNITY, INNATE; LIPOPROTEINS, HDL; MEMBRANE GLYCOPROTEINS; PROTOZOAN PROTEINS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS;

TRYPANOSOMA BRUCEI GAMBIENSE; TRYPANOSOMA BRUCEI RHODESIENSE;

EID: 84869178362     PISSN: 14714922     EISSN: 14715007     Source Type: Journal    
DOI: 10.1016/j.pt.2012.09.002     Document Type: Review

References (56)

1. Mansfield J.M., Paulnock D.M. Regulation of innate and acquired immunity in African trypanosomiasis. Parasite Immunol. 2005, 27:361-371.
2. Gibson W.C. Will the real Trypanosoma b. gambiense please stand up. Parasitol. Today 1986, 2:255-257.
3. Hajduk S.L., et al. Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein. J. Biol. Chem. 1989, 264:5210-5217.
4. Raper J., et al. Characterization of a novel trypanosome lytic factor from human serum. Infect. Immun. 1999, 67:1910-1916.
5. Rifkin M.R. Identification of the trypanocidal factor in normal human serum: high density lipoprotein. Proc. Natl. Acad. Sci. U.S.A. 1978, 75:3450-3454.
6. Bullard W., et al. Haptoglobin-hemoglobin receptor independent killing of African trypanosomes by human serum and trypanosome lytic factors. Virulence 2012, 3:72-76.
7. Shiflett A.M., et al. Human high density lipoproteins are platforms for the assembly of multi-component innate immune complexes. J. Biol. Chem. 2005, 280:32578-32585.
8. Smith A.B., et al. Killing of trypanosomes by the human haptoglobin-related protein. Science 1995, 268:284-286.
9. Rifkin M.R. Trypanosoma brucei: biochemical and morphological studies of cytotoxicity caused by normal human serum. Exp. Parasitol. 1984, 58:81-93.
10. Hager K.M., et al. Endocytosis of a cytotoxic human high density lipoprotein results in disruption of acidic intracellular vesicles and subsequent killing of African trypanosomes. J. Cell Biol. 1994, 126:155-167.
11. Shiflett A.M., et al. African trypanosomes: intracellular trafficking of host defense molecules. J. Eukaryot. Microbiol. 2007, 54:18-21.
12. Yorke W., et al. Studies in chemotherapy II: the action in vitro of normal human serum on the pathogenic trypanosomes, and its significance. Ann. Trop. Med. Parasitol. 1930, 24:115-163.
13. Hawking F. The resistance to human plasma of Trypanosoma brucei, T. rhodesiense and T. gambiense. II. Survey of strains from East Africa and Nigeria. Trans. R. Soc. Trop. Med. Hyg. 1976, 70:513-520.
14. Pays E., et al. The trypanolytic factor of human serum. Nat. Rev. 2006, 4:477-486.
15. Perez-Morga D., et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005, 309:469-472.
16. Vanhollebeke B., et al. Human serum lyses Trypanosoma brucei by triggering uncontrolled swelling of the parasite lysosome. J. Eukaryot. Microbiol. 2007, 54:448-451.
17. Drain J., et al. Haptoglobin-related protein mediates trypanosome lytic factor binding to trypanosomes. J. Biol. Chem. 2001, 276:30254-30260.
18. Vanhollebeke B., et al. A haptoglobin-hemoglobin receptor conveys innate immunity to Trypanosoma brucei in humans. Science 2008, 320:677-681.
19. Widener J., et al. Hemoglobin is a co-factor of human trypanosome lytic factor. PLoS Pathog. 2007, 3:1250-1261.
20. Stadnyk A., Gauldie J. The acute phase protein response during parasitic infection. Immunol. Today 1991, 12:A7-A12.
21. Nielsen M.J., et al. A unique loop extension in the serine protease domain of haptoglobin is essential for CD163 recognition of the haptoglobin-hemoglobin complex. J. Biol. Chem. 2007, 282:1072-1079.
22. Kristiansen M., et al. Identification of the haemoglobin scavenger receptor. Nature 2001, 409:198-201.
23. Nielsen M.J., et al. Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein. Blood 2006, 108:2846-2849.
24. Maeda N. Nucleotide sequence of the haptoglobin and haptoglobin-related gene pair. The haptoglobin-related gene contains a retrovirus-like element. J. Biol. Chem. 1985, 260:6698-6709.
25. Bishop J.R., et al. Insight into the mechanism of trypanosome lytic factor-1 killing of Trypanosoma brucei brucei. Mol. Biochem. Parasitol. 2001, 118:33-40.
26. Stephens N.A., Hajduk S.L. Endosomal localization of the serum resistance-associated protein in African trypanosomes confers human infectivity. Eukaryot. Cell 2011, 10:1023-1033.
27. Harrington J.M., et al. Membrane permeabilization by trypanosome lytic factor, a cytolytic human high density lipoprotein. J. Biol. Chem. 2009, 284:13505-13512.
28. Lecordier L., et al. C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense. PLoS Pathog. 2009, 5:e1000685.
29. Harrington J.M., et al. The plasma membrane of bloodstream-form African trypanosomes confers susceptibility and specificity to killing by hydrophobic peptides. J. Biol. Chem. 2010, 285:28659-28666.
30. Vanhamme L., et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 2003, 422:83-87.
31. Vanhollebeke B., Pays E. The trypanolytic factor of human serum: many ways to enter the parasite, a single way to kill. Mol. Microbiol. 2010, 76:806-814.
32. Gibson W. Will the real Trypanosoma brucei rhodesiense please step forward?. Trends Parasitol. 2002, 18:486-490.
33. Milner J.D., Hajduk S.L. Expression and localization of serum resistance associated protein in Trypanosoma brucei rhodesiense. Mol. Biochem. Parasitol. 1999, 104:271-283.
34. Xong H.V., et al. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell 1998, 95:839-846.
35. De Greef C., et al. A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. Mol. Biochem. Parasitol. 1989, 36:169-176.
36. Oli M.W., et al. Serum resistance-associated protein blocks lysosomal targeting of trypanosome lytic factor in Trypanosoma brucei. Eukaryot. Cell 2006, 5:132-139.
37. De Greef C., Hamers R. The serum resistance-associated (SRA) gene of Trypanosoma brucei rhodesiense encodes a variant surface glycoprotein-like protein. Mol. Biochem. Parasitol. 1994, 68:277-284.
38. Campillo N., Carrington M. The origin of the serum resistance associated (SRA) gene and a model of the structure of the SRA polypeptide from Trypanosoma brucei rhodesiense. Mol. Biochem. Parasitol. 2003, 127:79-84.
39. Engstler M., et al. Kinetics of endocytosis and recycling of the GPI-anchored variant surface glycoprotein in Trypanosoma brucei. J. Cell Sci. 2004, 117:1105-1115.
40. Grunfelder C.G., et al. Endocytosis of a glycosylphosphatidylinositol-anchored protein via clathrin-coated vesicles, sorting by default in endosomes, and exocytosis via RAB11-positive carriers. Mol. Biol. Cell 2003, 14:2029-2040.
41. Kabiri M., Steverding D. Studies on the recycling of the transferrin receptor in Trypanosoma brucei using an inducible gene expression system. Eur. J. Biochem. 2000, 267:3309-3314.
42. Schell D., et al. A transferrin-binding protein of Trypanosoma brucei is encoded by one of the genes in the variant surface glycoprotein gene expression site. EMBO J. 1991, 10:1061-1066.
43. Strickler J.E., Patton C.L. Trypanosoma brucei brucei: inhibition of glycosylation of the major variable surface coat glycoprotein by tunicamycin. Proc. Natl. Acad. Sci. U.S.A. 1980, 77:1529-1533.
44. Hager K.M., Hajduk S.L. Mechanism of resistance of African trypanosomes to cytotoxic human HDL. Nature 1997, 385:823-826.
45. Molina-Portela M.P., et al. Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model. J. Exp. Med. 2008, 205:1721-1728.
46. Berberof M., et al. A receptor-like flagellar pocket glycoprotein specific to Trypanosoma brucei gambiense. Mol. Biochem. Parasitol. 2001, 113:127-138.
47. Kieft R., et al. Mechanism of Trypanosoma brucei gambiense (group 1) resistance to human trypanosome lytic factor. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:16137-16141.
48. Capewell P., et al. Differences between Trypanosoma brucei gambiense groups 1 and 2 in their resistance to killing by trypanolytic factor 1. PLoS Negl. Trop. Dis. 2011, 5:e1287.
49. Faulkner S.D., et al. In vitro generation of human high-density-lipoprotein-resistant Trypanosoma brucei brucei. Eukaryot. Cell 2006, 5:1276-1286.
50. Symula R.E., et al. Trypanosoma brucei gambiense group 1 is distinguished by a unique amino acid substitution in the HpHb receptor implicated in human serum resistance. PLoS Negl. Trop. Dis. 2012, 6:e1728.
51. Green H.P., et al. Evidence for a Trypanosoma brucei lipoprotein scavenger receptor. J. Biol. Chem. 2003, 278:422-427.
52. Thomson R., et al. Hydrodynamic gene delivery of baboon trypanosome lytic factor eliminates both animal and human-infective African trypanosomes. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:19509-19514.
53. Baral T.N., et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat. Med. 2006, 12:580-584.
54. Lukes J., Raper J. Prophylactic antiparasitic transgenesis for human parasitic disease?. Mol. Ther. 2010, 18:1745-1747.
55. Stijlemans B., et al. High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis. PLoS Pathog. 2011, 7:e1002072.
56. Goringer H.U. Parasite-specific aptamers as biosynthetic reagents and potential pharmaceuticals. Trends Parasitol. 2012, 28:106-113.